Kestra Medical Technologies Reports 52% Revenue Growth to $19.4 Million Despite Increased Net Loss

Kestra Medical Technologies, Ltd. reported significant financial developments in its latest 10-Q filing for the quarter ending July 31, 2025. The company generated revenue of $19.4 million, marking a 52% increase from $12.8 million in the same period last year. This growth was primarily driven by a 54% increase in the number of patients using its ASSURE Wearable Cardioverter Defibrillator (WCD) and improvements in revenue cycle management. Despite the revenue increase, Kestra reported a net loss of $25.8 million, compared to a loss of $20.3 million in the prior year, reflecting ongoing investments in research and development and operational expansion.

The company's operating expenses rose significantly, totaling $37.7 million for the quarter, up from $22.6 million a year earlier. This increase was largely attributed to a $14.5 million rise in selling, general, and administrative expenses, driven by higher personnel costs and professional service fees associated with its transition to a public company. Research and development expenses also increased by 18% to $4.0 million, reflecting ongoing efforts to enhance product offerings and support clinical studies.

In terms of operational metrics, Kestra's customer base expanded significantly, contributing to the revenue growth. The company reported a gross profit of $8.9 million, which is a 111% increase from $4.2 million in the previous year, indicating improved cost management and operational efficiencies. However, the overall loss from operations widened to $28.9 million, up from $18.4 million, as the company continues to invest heavily in scaling its commercial operations and enhancing its product offerings.

As of July 31, 2025, Kestra had cash and cash equivalents of $201.2 million, down from $237.6 million at the end of the previous quarter. The decrease in cash was primarily due to negative operating cash flows of $26.3 million, which were higher than the $17.5 million reported in the same quarter last year. The company’s accumulated deficit now stands at $546.1 million, reflecting its ongoing investment strategy and the costs associated with its growth initiatives.

Looking ahead, Kestra Medical Technologies remains optimistic about its growth trajectory, bolstered by the recent IPO that raised approximately $215.8 million in net proceeds. The company plans to continue expanding its commercial team and enhancing its product offerings to capture a larger share of the market for wearable cardiac devices. However, management cautioned that future performance may be impacted by market conditions, reimbursement rates, and the ability to scale operations effectively.